Literature DB >> 24001532

Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study.

Adnan Tufail1, Nirodhini Narendran, Praveen J Patel, Sobha Sivaprasad, Winfried Amoaku, Andrew C Browning, Olayinka Osoba, Richard Gale, Sheena George, Andrew J Lotery, Mohammed Majid, Martin McKibbin, Geeta Menon, Christopher Andrews, Christopher Brittain, Aaron Osborne, Yit Yang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24001532     DOI： 10.1016/j.ophtha.2013.06.010

Source DB:  PubMed          Journal:  Ophthalmology        ISSN： 0161-6420            Impact factor:   12.079


× No keyword cloud information.
  32 in total

1.  Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab.

Authors:  Salomon Y Cohen; Sylvia Nghiem-Buffet; Typhaine Grenet; Lise Dubois; Sandrine Ayrault; Franck Fajnkuchen; Corinne Delahaye-Mazza; Gabriel Quentel; Ramin Tadayoni
Journal:  Jpn J Ophthalmol       Date:  2014-11-22       Impact factor: 2.447

2.  A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.

Authors:  Alfredo Pece; Paolo Milani; Carla Monteleone; Costantino John Trombetta; Giuseppe De Crecchio; Giuseppe Fasolino; Domenica Matranga; Salvatore Cillino; Maria Vadalà
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-12-13       Impact factor: 3.117

3.  Choroidal neovascularization secondary to pathological myopia-macular Bruch membrane defects as prognostic factor to anti-VEGF treatment.

Authors:  João Coelho; André Ferreira; Ana Carolina Abreu; Sílvia Monteiro; Maria João Furtado; Miguel Gomes; Miguel Lume
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-03-21       Impact factor: 3.117

4.  Retinal pigmental epithelium elevation and external limiting membrane interruption in myopic choroidal neovascularization: correlation with activity.

Authors:  Xiaoyan Ding; Zongyi Zhan; Limei Sun; Yu Yang; Songshan Li; Aiyuan Zhang; Xiaoling Luo; Lin Lu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-07-07       Impact factor: 3.117

Review 5.  Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.

Authors:  Ying Zhu; Ting Zhang; Gezhi Xu; Lijun Peng
Journal:  Cochrane Database Syst Rev       Date:  2016-12-15

6.  Intravitreal aflibercept for myopic choroidal neovascularization.

Authors:  Alfredo Pece; Paolo Milani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-06-11       Impact factor: 3.117

7.  Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: long-term outcomes.

Authors:  Valentina Sarao; Daniele Veritti; Sara Macor; Paolo Lanzetta
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-06-18       Impact factor: 3.117

Review 8.  Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy.

Authors:  Kelvin Yi Chong Teo; Wei Yan Ng; Shu Yen Lee; Chui Ming Gemmy Cheung
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

9.  Long-term outcomes of the intravitreal injection of ranibizumab for the treatment of choroidal neovascularization secondary to pathologic myopia.

Authors:  Ewa Wasiluk; Malgorzata Wojnar; Iwona Obuchowska; Zofia Mariak
Journal:  Int Ophthalmol       Date:  2019-12-02       Impact factor: 2.031

10.  Outcome Predictors of SD-OCT-Driven Intravitreal Ranibizumab in Choroidal Neovascularization due to Myopia.

Authors:  Maria-Magdalena Guichard; Géraldine Peters; Cengiz Tuerksever; Christian Pruente; Katja Hatz
Journal:  Ophthalmologica       Date:  2019-08-06       Impact factor: 3.250
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.